Pro B et al. -In the current study it was shown that brentuximab vedotin is a curative treatment option in patients with anaplastic large cell lymphoma (ALCL).

Methods

• After a median period of approximately 6 years from first treatment, the durability of remission, PFS, OS, and safety outcomes of patients were determined.

Results

• Of 58 patients, no progression was observed beyond 40 months. Patients with a CR (38 of 58), continued to demonstrate improved outcomes with neither median OS nor PFS reached.
• Among patients who were in remission at study end, 16 had not received any new treatment after single-agent brentuximab vedotin other than consolidative SCT (n=8), and the remaining 8 patients remained in sustained remission.
• 33 patients had peripheral neuropathy.